THE DEAL, AT A GLANCE
From the announcementEntrada Therapeutics
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedEntrada Therapeutics raised $150M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersEntrada Therapeutics is financing a muscle and neuron delivery strategy for RNA therapeutics, with the Growth Round directed toward advancing ENTR-601 in DMD exon…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Entrada Therapeutics · Financing Record
Explore source-linked visual explanations for Entrada Therapeutics. Unsupported claims are withheld while source review continues.
Record 1445 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →